| pubmed-article:20410926 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20410926 | lifeskim:mentions | umls-concept:C0001483 | lld:lifeskim |
| pubmed-article:20410926 | lifeskim:mentions | umls-concept:C0017296 | lld:lifeskim |
| pubmed-article:20410926 | lifeskim:mentions | umls-concept:C0034802 | lld:lifeskim |
| pubmed-article:20410926 | lifeskim:mentions | umls-concept:C0431085 | lld:lifeskim |
| pubmed-article:20410926 | lifeskim:mentions | umls-concept:C0071216 | lld:lifeskim |
| pubmed-article:20410926 | lifeskim:mentions | umls-concept:C0919437 | lld:lifeskim |
| pubmed-article:20410926 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:20410926 | pubmed:dateCreated | 2010-8-12 | lld:pubmed |
| pubmed-article:20410926 | pubmed:abstractText | We have assessed the ability of bispecific fusion proteins to improve adenovirus-mediated transfer of therapeutic and marker transgenes. We constructed an expression vector that can be easily modified to synthesize a variety of fusion proteins for retargeting adenoviral gene therapy vectors to cell surface markers, which are differentially expressed between normal and cancer cells. Adenoviral transduction can be improved in a number of tumour cell lines which overexpress EGFR (epidermal growth factor receptor) or uPAR (urokinase-type plasminogen activator receptor), but which have only low levels of endogenous hCAR (human coxsackie B and adenovirus receptor) expression. Up to 40-fold improvement in beta-galactosidase transgene expression was seen using an EGFR retargeting protein, and up to 16-fold using a second fusion protein targeting uPAR. In vitro, our uPAR retargeting fusion protein improved the sensitivity to adenoviral herpes simplex virus thymidine kinase/ganciclovir by an order of magnitude, whereas in vivo, our EGFR retargeting protein is able to significantly delay tumour growth in rodent animal models in a dose-dependent manner. The 'cassette' design of our fusion protein constructs offers a flexible method for the straightforward synthesis of multiple adenoviral retargeting proteins, directed against a variety of tumour-associated antigens, for use in clinical trials. | lld:pubmed |
| pubmed-article:20410926 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20410926 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20410926 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20410926 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20410926 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20410926 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20410926 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20410926 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20410926 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20410926 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20410926 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20410926 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20410926 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20410926 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20410926 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:20410926 | pubmed:issn | 1476-5462 | lld:pubmed |
| pubmed-article:20410926 | pubmed:author | pubmed-author:SelbyP JPJ | lld:pubmed |
| pubmed-article:20410926 | pubmed:author | pubmed-author:SteeleLL | lld:pubmed |
| pubmed-article:20410926 | pubmed:author | pubmed-author:HallG DGD | lld:pubmed |
| pubmed-article:20410926 | pubmed:author | pubmed-author:BurdonDD | lld:pubmed |
| pubmed-article:20410926 | pubmed:author | pubmed-author:VileR GRG | lld:pubmed |
| pubmed-article:20410926 | pubmed:author | pubmed-author:HarveyT JTJ | lld:pubmed |
| pubmed-article:20410926 | pubmed:author | pubmed-author:CooperP APA | lld:pubmed |
| pubmed-article:20410926 | pubmed:author | pubmed-author:IngramNN | lld:pubmed |
| pubmed-article:20410926 | pubmed:author | pubmed-author:ShnyderS DSD | lld:pubmed |
| pubmed-article:20410926 | pubmed:author | pubmed-author:ChesterJ DJD | lld:pubmed |
| pubmed-article:20410926 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20410926 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:20410926 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20410926 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20410926 | pubmed:pagination | 1000-10 | lld:pubmed |
| pubmed-article:20410926 | pubmed:dateRevised | 2011-10-11 | lld:pubmed |
| pubmed-article:20410926 | pubmed:meshHeading | pubmed-meshheading:20410926... | lld:pubmed |
| pubmed-article:20410926 | pubmed:meshHeading | pubmed-meshheading:20410926... | lld:pubmed |
| pubmed-article:20410926 | pubmed:meshHeading | pubmed-meshheading:20410926... | lld:pubmed |
| pubmed-article:20410926 | pubmed:meshHeading | pubmed-meshheading:20410926... | lld:pubmed |
| pubmed-article:20410926 | pubmed:meshHeading | pubmed-meshheading:20410926... | lld:pubmed |
| pubmed-article:20410926 | pubmed:meshHeading | pubmed-meshheading:20410926... | lld:pubmed |
| pubmed-article:20410926 | pubmed:meshHeading | pubmed-meshheading:20410926... | lld:pubmed |
| pubmed-article:20410926 | pubmed:meshHeading | pubmed-meshheading:20410926... | lld:pubmed |
| pubmed-article:20410926 | pubmed:meshHeading | pubmed-meshheading:20410926... | lld:pubmed |
| pubmed-article:20410926 | pubmed:meshHeading | pubmed-meshheading:20410926... | lld:pubmed |
| pubmed-article:20410926 | pubmed:meshHeading | pubmed-meshheading:20410926... | lld:pubmed |
| pubmed-article:20410926 | pubmed:meshHeading | pubmed-meshheading:20410926... | lld:pubmed |
| pubmed-article:20410926 | pubmed:meshHeading | pubmed-meshheading:20410926... | lld:pubmed |
| pubmed-article:20410926 | pubmed:meshHeading | pubmed-meshheading:20410926... | lld:pubmed |
| pubmed-article:20410926 | pubmed:meshHeading | pubmed-meshheading:20410926... | lld:pubmed |
| pubmed-article:20410926 | pubmed:meshHeading | pubmed-meshheading:20410926... | lld:pubmed |
| pubmed-article:20410926 | pubmed:meshHeading | pubmed-meshheading:20410926... | lld:pubmed |
| pubmed-article:20410926 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20410926 | pubmed:articleTitle | Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor. | lld:pubmed |
| pubmed-article:20410926 | pubmed:affiliation | Leeds Institute of Molecular Medicine, St James's University Hospital, Leeds, UK. | lld:pubmed |
| pubmed-article:20410926 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20410926 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
